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The results of this study suggest that Calmare provides significantly 
more pain relief than sham at 3 weeks post-intervention and can 
reduce pain intensity, interference and pain sensitivity in individuals 
with persistent low back pain. The differential expression of pain 
genes between the intervention and sham group suggests that it may 
exert an effect by downregulating pain receptors and proteins involved 
in maintaining persistent pain. Evaluation of long-term outcomes after 
Calmare, particularly functional status, analgesic use and health care 
utilization, is warranted in future studies. 
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Abstract 
We present the results of  a double-blinded randomized sham-
controlled research study of  a non-pharmacologic low back pain 
intervention.  Calmare therapy is an neurocutanous electrical 
stimulation approach for pain management. The intervention group 
received Calmare therapy and the other received sham. Differences 
in pain severity and interference scores, pain sensitivity measures and 
gene expression profiles are reported. Patterns of  downregulated 
gene expression suggest that Calmare may alter proteins involved in 
pain transduction may have implications for the treatment of  other 
chronic pain conditions.  
Introduction 
 Persistent low back pain  (LBP) is one of  the nation’s most 
expensive medical conditions and a leading cause of  disability. 
 Several lines of  evidence support the premise that LBP develops 
as a consequence of  sensitization of  nociceptors and neuronal 
circuits with modifications in the expression of  genes that 
encode pain signaling molecules and their receptors.  
 Gene associated with neurotropins, inflammatory mediators and 
catecholamines are most often modified. 
 Calmare, a non-invasive bioengineering-based method of  pain 
treatment, was designed to interrupt the mechanisms of  
persistent  pain by scrambling the pain signaling using electrical 
waveforms that  mimic endogenous action potentials. 
 A double–blinded randomized sham controlled pilot study was 
conducted at VCU School of  Nursing. Persistent LBP was 
defined as pain without a specific cause or need for surgical 
intervention in the  region of  the low back below  T2 and above 
the buttock crease, persistent  for  at least or more than 3 
months for more than or equal to 4 days a week at a level of  4 
or greater. Participants received a standard protocol of  Calmare  
or sham using the Calmare device to deliver a non-therapeutic 
threshold. Data collected included  study questionnaires, 
quantitative sensory testing  (QST), and blood samples. 
Results/Discussion 
  
Conclusion 
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There was a statistically significant difference in the “worst” pain score 
between the Calmare and sham groups at the 1 and 3 week follow-up visits. 
Pain interference was significantly different between groups at the 3 week 
follow-up visit, with significantly lower pain interference in the Calmare 
group. The “worst” pain and interference scores of the BPI showed a 
significant decrease in the Calmare group from baseline to the 3 week 
follow-up visit whereas the sham treatment group did not change over time. 
In the Calmare group, 7 (47%) participants had a >50% reduction in the 
“worst” pain score from baseline to the 3-week follow-up visit, 5 (33%) 
participants had a 30-49% reduction, and 3 (20%) had a 20-29% reduction.   
Measures of pain sensitivity (heat pain threshold, single stimulus rating, 
and pressure pain threshold) were significantly different between groups at 
the 3 week follow-up visit. The higher level thresholds to heat pain and 
pressure pain in the Calmare group at 3 weeks follow-up reflect that a 
higher stimulus intensity is required to cause a perception of pain. 
Consistent with these findings, they also rated their perception of pain 
lower to the single heat stimulus. These findings demonstrate less pain 
sensitivity in the Calmare group compared to the sham group at the 3 week 
follow-up visit. However, the within group changes in pain sensitivity 
measures from baseline to 3 weeks did not reach a level of statistical 
significance. 
There were no significant differences in the baseline mRNA levels of the 
84 candidate genes between the Calmare and sham groups. However, 
differential expression of 17 candidate genes was observed between 
baseline and 3 weeks post-intervention. Using a p-value threshold of <0.01, 
the fold regulation of these genes were significantly different between the 
Calmare and sham group: BDKRB1, CACNA1B, CCKBR, CHRNA4, 
GDNF, GRM1, HTR2A, KCNIP3, KCNQ2, NGF, NTRK1, OPRD1, OPRK1, 
OPRM1, PENK, PLA2G1B, and TAC1. The table below shows the 
differential fold regulation in the Calmare group at 3 weeks post-
intervention accompanied by the associated p-value. 
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Gene Fold Regulation p-value 
BDKRB1 -2.468 0.0069 
CACNA1B -1.518 0.0091 
CCKBR -1.804 0.0150 
CHRNA4 -1.924 0.0053 
GDNF -2.141 0.0036 
GRM1 -1.715 0.0033 
HTR2A -2.630 0.0100 
KCNIP3 -2.587 0.0100 
KCNQ2 -1.550 0.0172 
NGF -2.599 0.0040 
NTRK1 -1.980 0.0035 
OPRD1 -1.812 0.0049 
OPRK1 -2.083 0.0110 
OPRM1 -1.699 0.0100 
PENK -1.850 0.0042 
PLA2G1B -1.816 0.0020 
TAC1 -1.852 0.0150 
Differential Gene Expression in the Calmare Group at 3 Weeks Post-Treatment 
